Pharmaceutical Licence in Lithuania

AT A GLANCE

Pharmaceutical activities in Lithuania — wholesale distribution of medicines, retail pharmacy operation, and the import of medicinal products — require authorisation from the State Medicines Control Agency (Valstybinė vaistų kontrolės agentūra — VVKT) before any operations can begin.
There are three main pharmaceutical authorisation types: the wholesale distribution authorisation (GDP), the pharmacy operating licence, and the medicine import authorisation — each with distinct requirements and its own VVKT inspection process.
The Qualified Person (QP) — a designated specialist with pharmaceutical qualifications and experience — is a mandatory requirement for wholesale distribution and manufacturing authorisations and cannot be replaced by a general manager or director.
A pre-authorisation inspection of the premises by VVKT inspectors is required for all three licence types — the premises must meet Good Distribution Practice (GDP) or Good Manufacturing Practice (GMP) standards at the time of inspection.
We advise on pharmaceutical licence applications in Lithuania — structure assessment, QP identification, document preparation, VVKT submission, and inspection preparation — coordinating with EU pharmaceutical regulatory specialists where cross-border activities are involved.

Short answer

A pharmaceutical licence in Lithuania is the authorisation issued by the State Medicines Control Agency (VVKT) to companies engaged in the wholesale distribution, retail dispensing, or import of medicinal products. The three main authorisation types are the wholesale distribution authorisation (governed by Good Distribution Practice — GDP), the pharmacy operating licence (for retail pharmacies dispensing to the public), and the medicine import authorisation (for companies importing from outside the EU). All three require a pre-authorisation VVKT inspection and the designation of a Qualified Person or Responsible Pharmacist. Processing times range from 30 to 90 days depending on the authorisation type and inspection scheduling.

The Regulatory Framework for Pharmaceuticals in Lithuania

Lithuania’s pharmaceutical sector is regulated by the Law on Pharmacy (Farmacijos įstatymas) and by directly applicable EU pharmaceutical legislation — principally Directive 2001/83/EC on the Community code for medicinal products and Commission Delegated Regulation (EU) 2016/161 on falsified medicines. The State Medicines Control Agency (VVKT) is the national competent authority for pharmaceutical licensing and sits within the European network of national medicines agencies coordinated by the European Medicines Agency (EMA).

Being part of the EU pharmaceutical regulatory network means that a Lithuanian wholesale distribution authorisation is recognised across the EU — a licensed Lithuanian distributor can supply medicines to pharmacies and hospitals in other EU member states without requiring separate authorisations in each country, provided the products are correctly authorised for the relevant markets. For companies that want to use Lithuania as a hub for EU pharmaceutical distribution, this passporting of the wholesale authorisation is commercially significant.

Who is regulated

The VVKT authorisation requirement applies to any company engaged in: the wholesale distribution of medicinal products (supplying pharmacies, hospitals, clinics, and other authorised recipients); the retail dispensing of medicines to patients through a pharmacy; the importation of medicinal products from outside the EU; or the manufacture of medicinal products. Retailers of non-prescription health supplements and cosmetics are not subject to the pharmaceutical licensing framework unless the products they sell are classified as medicinal products.

Medicines classification in Lithuania

Understanding whether a product is a ‘medicinal product’ under Lithuanian and EU law is the starting point for any pharmaceutical licensing question. A product is a medicinal product if it is presented as having therapeutic or preventive properties, or if it has a pharmacological, immunological, or metabolic action capable of treating or preventing disease. Many products — including some herbal preparations, vitamins at therapeutic doses, and certain medical devices — may be classified as medicinal products even if the manufacturer does not present them as medicines. Classification determines whether the pharmaceutical licensing framework applies. We advise on product classification as part of our initial assessment for new market entrants.

The Three Main Pharmaceutical Authorisations

Wholesale Distribution Authorisation (GDP Licence)

The wholesale distribution authorisation is required for any company that supplies medicinal products to pharmacies, hospitals, clinics, other wholesale distributors, or manufacturers. It is the standard authorisation for pharmaceutical importers, distributors, and trading companies operating in the medicine supply chain. The authorisation is governed by the EU Good Distribution Practice (GDP) guidelines and requires a comprehensive quality management system.

Mandatory for any company supplying medicinal products to authorised recipients in Lithuania or other EU member states
Requires a designated Qualified Person (QP) with pharmaceutical qualifications and experience
Premises must meet GDP standards: temperature-controlled storage, segregation of products, security against unauthorised access, quarantine area for suspect products
Quality management system (QMS) must be documented and operational before inspection
Recall procedure — a documented and tested procedure for withdrawing products from the market
Supplier and customer verification — procedures for verifying that suppliers and customers are themselves authorised
VVKT pre-authorisation inspection of premises against GDP guidelines
5-year validity — authorisation renewed every 5 years; subject to VVKT periodic inspections in between

Pharmacy Operating Licence

The pharmacy operating licence authorises a company or individual to operate a retail pharmacy — dispensing prescription and non-prescription medicines directly to patients and the public. In Lithuania, pharmacy operation is a regulated profession: the responsible pharmacist must hold a recognised pharmacy degree and be registered with the Lithuanian Pharmacists' Chamber (Lietuvos farmacininkų rūmai).

Mandatory for any premises dispensing medicines to patients or the public
Responsible pharmacist — a licensed pharmacist registered with the Lithuanian Pharmacists' Chamber, designated as the person responsible for the pharmacy
Physical layout requirements — dispensing counter, patient consultation area, prescription storage, non-prescription display area, storage area meeting temperature and humidity requirements
Prescription handling procedures — documented procedures for receiving, verifying, dispensing, and recording prescriptions
Cold chain management — refrigerated storage for medicines requiring cold storage; temperature monitoring system
VVKT pre-opening inspection — premises inspected against the layout and operational requirements before the licence is issued
5-year validity — subject to VVKT periodic inspections; the responsible pharmacist must remain registered throughout
Distance rules — some municipalities restrict the minimum distance between pharmacies; we confirm applicable rules for each location

Medicine Import Authorisation

The medicine import authorisation is required for companies that import medicinal products from outside the EU/EEA into Lithuania. Any company that is not itself the marketing authorisation holder (MAH) for the products it imports must hold an import authorisation. The authorisation is closely related to the wholesale distribution authorisation — most importers hold both simultaneously.

Required for importing medicinal products from non-EU countries (including the UK post-Brexit) into Lithuania
Qualified Person — a QP must certify each batch of imported medicines before it is released for distribution within the EU
Batch testing — imported medicinal products must be tested in an EU-licensed laboratory unless a mutual recognition agreement with the exporting country applies
Premises — the importer must have storage premises meeting GDP standards where imported products are held pending QP certification and batch release
Documentation — import records, batch certificates, QP release records, and customs documentation must be maintained for 5 years
UK medicines post-Brexit — medicines manufactured in the UK and imported into Lithuania require full batch testing in an EU-licensed laboratory (no mutual recognition currently applies)
US-manufactured medicines — under the EU-US mutual recognition agreement, batch testing in the EU may not be required for certain products from FDA-licensed manufacturers

The Qualified Person (QP): The Critical Role in Pharmaceutical Licensing

The Qualified Person is the single most important — and most frequently misunderstood — requirement in pharmaceutical wholesale distribution and import licensing. The QP is not simply a manager or a compliance officer: they are a designated specialist with specific educational and experiential qualifications who bears personal legal responsibility for certifying that each batch of medicinal products meets the applicable quality standards before release.

QP qualifications — what is required

Under EU Directive 2001/83/EC Article 49, a Qualified Person must hold a diploma in pharmacy, medicine, veterinary medicine, chemistry, pharmaceutical chemistry and technology, or biology from a recognised university or equivalent institution. In addition, the QP must have at least two years of practical experience in one or more authorised undertakings in the fields of quality control, production, or release of medicinal products. The combination of academic qualification and practical experience is non-negotiable — neither alone is sufficient.

What the QP certifies

For each batch of medicinal products that the licensed company releases for distribution or sale, the QP must certify that: the batch has been manufactured and controlled in accordance with the requirements of its marketing authorisation and applicable GMP/GDP standards; the batch has been tested in accordance with the testing requirements; and all relevant EU requirements have been complied with. The QP signs the batch release documentation personally and is personally accountable for each batch they certify. This personal accountability means that the QP must have genuine access to the batch records and quality data — a nominal QP appointment without real involvement in the release process does not satisfy the regulatory requirement.

QP for wholesale distribution vs. manufacturing

The QP role in wholesale distribution is somewhat less demanding than in manufacturing — the wholesale QP certifies batch receipt and storage conditions rather than the manufacturing process itself. However, for imported medicines, the wholesale/import QP must certify that batch testing has been completed in an EU-licensed laboratory (unless a mutual recognition agreement applies) and that the batch meets all applicable specifications. For manufacturing, the QP certifies the entire manufacturing process and is directly involved in production quality control.

Finding a qualified QP in Lithuania

Qualified Persons who are willing to serve as the named QP for a pharmaceutical licence are not universally available — particularly for smaller distributors that cannot offer full-time employment. The QP may be employed part-time, contracted as a consultant, or outsourced through a specialist pharmaceutical services provider. The VVKT accepts QP arrangements where the QP is not a full-time employee, provided the QP has genuine access to the company’s quality systems and is available when needed to review and release batches. We advise on QP sourcing and structure the QP arrangement correctly for each licensing engagement.

 QP outsourcing — is it permitted?

Yes — the VVKT accepts outsourced QP arrangements provided the arrangement is documented in a written agreement that defines the QP’s scope of responsibility, access rights, and obligations. The agreement must be available for VVKT inspection. The QP must be reachable and available whenever batch release decisions are required. Outsourced QP arrangements are common among smaller pharmaceutical distributors and importers who do not have sufficient volume to justify a full-time in-house QP. We advise on the structure of QP outsourcing agreements and can introduce VVKT-registered QPs through our specialist network.

Good Distribution Practice (GDP): What VVKT Inspects

Good Distribution Practice is the quality framework that governs the wholesale distribution of medicinal products in the EU. It is set out in the EU GDP Guidelines (2013/C 343/01) and is the standard against which VVKT inspectors assess wholesale distribution premises before issuing and renewing the authorisation. Understanding what the inspection looks for — and preparing the premises accordingly — is the most effective way to achieve first-time authorisation.

Quality management system

The GDP quality management system (QMS) is the documented framework that defines how the company manages pharmaceutical distribution quality. It must include: a quality manual describing the overall quality framework; standard operating procedures (SOPs) for all key activities (goods receipt, storage, picking and packing, dispatch, returns, recalls, and customer complaints); a system for managing deviations and corrective and preventive actions (CAPAs); a qualification and training programme for all relevant staff; and a procedure for self-inspection. The QMS must be operational — not merely documented — at the time of inspection.

Premises and equipment

The warehouse premises must provide: appropriate temperature and humidity conditions for all stored products (typically ambient 15–25°C; cold chain 2–8°C for products requiring refrigeration); a separate quarantine area where products of uncertain status are held pending release or rejection; segregated storage for returned goods, rejected goods, and suspect or falsified medicines; and a goods receipt area where incoming deliveries can be checked before being accepted into stock. Temperature mapping of the storage areas must be conducted before the first inspection and repeated after any significant changes to the premises or equipment. Temperature monitoring must be continuous — validated monitoring systems are required for cold chain storage.

Supplier and customer verification

Before receiving medicines from a supplier or selling to a customer, the wholesale distributor must verify that the other party is authorised. For suppliers, this means confirming that the supplier holds a valid manufacturing authorisation, marketing authorisation, or wholesale distribution authorisation as applicable. For customers, this means confirming that the pharmacy, hospital, or distributor is authorised to receive medicines. The VVKT maintains a public database of authorised wholesale distributors and pharmacies — we advise on the verification procedure and document it in the company’s SOPs.

Falsified medicines — track and trace

EU Directive 2011/62/EU (the Falsified Medicines Directive) and Delegated Regulation (EU) 2016/161 require that prescription medicines carry a unique identifier (2D barcode) and a tamper-evident device, and that these identifiers are verified and decommissioned at the point of dispensing. Wholesale distributors must have systems to check the authenticity of medicines they receive and dispatch, and to report suspect falsified medicines to the VVKT. Compliance with the falsified medicines framework is assessed during GDP inspections.

The Pharmaceutical Licence Application Process

The VVKT application process for pharmaceutical authorisations is more substantive than most other licensing applications in Lithuania — it involves documented quality systems, a named QP, and a pre-authorisation inspection. We manage the complete process.

Authorisation type assessment
We confirm the correct authorisation type for the intended pharmaceutical activity — wholesale distribution, pharmacy operation, import, or a combination. For companies that plan to both import and distribute, the relationship between the two authorisations is clarified at this stage. We also assess whether any products the company intends to handle are classified as medicinal products and therefore within scope.

QP identification and engagement
We identify a suitable Qualified Person for the licence — either from the client’s existing team (if a qualifying individual is already employed) or through our specialist pharmaceutical network. The QP’s qualifications and experience are verified against the EU Directive 2001/83/EC requirements. The QP arrangement is documented in a written agreement before it is submitted to VVKT.

Premises assessment and GDP gap analysis
We assess the intended premises against GDP requirements — identifying gaps in temperature control, quarantine segregation, monitoring systems, and storage capacity before the VVKT inspection. A GDP gap analysis report identifies what must be remediated before the application is submitted. This step prevents first-time inspection failures.

Quality management system preparation
We advise on the key SOPs and quality documents the VVKT will expect to see at inspection. For new companies, we prepare a GDP quality manual and core SOPs covering goods receipt, storage, dispatch, returns, recalls, and self-inspection. For companies with existing systems, we review and update documentation to align with Lithuanian and EU GDP requirements.

Document preparation and application submission
We prepare the complete VVKT application package: completed application forms, company registration extract, QP documentation (CV, qualifications, designation agreement), premises details and floor plan, equipment list, GDP quality manual summary, and personnel qualifications summary. The application is submitted electronically through the VVKT’s e-services portal.

VVKT review and query response
The VVKT reviews the application documentation and may raise questions before scheduling the inspection — particularly about the QP’s qualifications or the premises’ compliance with GDP standards. We manage all VVKT correspondence and prepare written responses to any queries promptly.

Pre-authorisation inspection
VVKT inspectors conduct an on-site inspection of the premises. Inspectors assess the physical premises, review the quality management system documentation, interview the QP and responsible staff, and test key procedures. We prepare the client for the inspection — conducting a mock walkthrough, briefing the QP and relevant staff, and ensuring all documentation is organised for inspector review.

Authorisation issued
Following a satisfactory inspection, the VVKT issues the pharmaceutical authorisation. The authorisation is valid for 5 years and must be renewed before expiry. Any changes to the authorised activities, premises, or QP designation during the 5-year period must be notified to the VVKT — major changes may trigger an additional inspection. We advise on post-authorisation change notification requirements.

Controlled Substances: Additional Requirements

Pharmaceutical companies handling controlled substances — narcotics, psychotropic substances, and their precursors — face additional regulatory requirements beyond the standard pharmaceutical authorisation framework. These requirements apply under the Law on the Control of Narcotic and Psychotropic Substances and Under Law on Precursors of Drugs and Psychotropic Substances.

What requires a controlled substances licence

Any company that manufactures, imports, exports, distributes, stores, or uses controlled substances — including Schedule I–IV narcotics and psychotropic substances as classified under Lithuanian law — requires a separate controlled substances licence from the VVKT. This applies to wholesale distributors who handle prescription painkillers (opioids), anxiolytics, hypnotics, and other controlled medicines, as well as to pharmacies that dispense such medicines. The controlled substances licence is additional to and separate from the standard wholesale distribution authorisation or pharmacy licence.

Additional requirements for controlled substances

Secure, separately locked storage — controlled substances must be stored in a dedicated, locked area with restricted access and an access control log
Transaction records — every movement of controlled substances (receipt, dispatch, dispensing, return, and destruction) must be recorded in a dedicated register maintained separately from standard stock records
Quarterly reporting to VVKT — companies must report controlled substance movements to the VVKT quarterly
Annual stock reconciliation — an annual physical count of controlled substances must be conducted and reconciled to the transaction records
Staff access controls — only specifically authorised staff may have access to the controlled substances storage area
Destruction protocol — expired or returned controlled substances must be destroyed in the presence of a VVKT representative using a documented protocol

 Precursors — a separate category

Drug precursors — chemical substances that can be used in the illicit manufacture of controlled drugs — are regulated separately from controlled medicines under EU Regulation 273/2004 and 111/2005. Companies that handle Category 1 precursors (such as ephedrine and certain acetates) must be licensed by the VVKT under the precursor control framework, independent of any pharmaceutical licence they may hold. We advise on precursor licensing alongside pharmaceutical licensing for companies whose products or raw materials fall within the precursor categories.

Pharmaceutical Authorisations: At a Glance

Feature	Wholesale Distribution (GDP)	Pharmacy Operating Licence	Import Authorisation
Issuing authority	VVKT	VVKT	VVKT
Legal basis	Directive 2001/83/EC + GDP	Law on Pharmacy	Directive 2001/83/EC Art. 40
Qualified Person required	Yes — QP with EU qualifications	Responsible Pharmacist	Yes — QP for batch release
Premises inspection	Pre-authorisation GDP inspection	Pre-opening layout check	Pre-authorisation GDP inspection
Key quality standard	EU GDP Guidelines 2013	VVKT layout and operational standards	EU GDP + batch testing requirements
Controlled substances	Separate controlled substances licence required	Separate licence required	Separate licence required
EU passporting	Yes — recognised across EU	No — Lithuania only	Yes — batch release valid across EU
Processing time	60–90 days	30–60 days	60–90 days
Validity	5 years	5 years	5 years
Renewal inspection	VVKT periodic reinspection	VVKT periodic reinspection	VVKT periodic reinspection

Pharmaceutical Licence Service Pricing

Pharmaceutical licensing is a substantive engagement — the QP identification, GDP gap analysis, quality system documentation, and inspection preparation are each specialist workstreams in their own right. We quote per engagement after an initial assessment call. The indicative service fees below reflect typical engagements; complex or multi-site authorisations are quoted individually.

Service	Price
Initial pharmaceutical licensing assessment — Confirming authorisation type, QP requirements, premises scope, and processing timeline	€1,000
Wholesale distribution authorisation (GDP) — application management — Includes QP identification advisory, GDP gap analysis, document preparation, VVKT submission and inspection prep	On request
Pharmacy operating licence — application management — Responsible pharmacist advisory, layout assessment, document preparation, and VVKT inspection preparation	On request
Medicine import authorisation — application management — QP identification, batch testing advisory, document preparation, VVKT submission and inspection preparation	On request
GDP gap analysis — premises and quality system — Assessment of premises and existing QMS against EU GDP guidelines; written gap report with remediation plan	€1,600
GDP quality manual and core SOPs preparation — Drafting GDP quality manual and core SOPs for new wholesale distribution operations	On request
QP identification and engagement advisory — Identifying and assessing suitable QP candidates; QP agreement structuring	€1,200
VVKT inspection preparation — mock walkthrough — Pre-inspection walkthrough of premises and documentation review; staff briefing	€800
Controlled substances licence application — Application for controlled substances handling licence; additional to standard pharmaceutical authorisation	On request
Authorisation renewal — per authorisation — 5-year renewal application and supporting documentation; quoted at renewal	On request
Post-authorisation change notification — VVKT notification for changes in QP, premises, or authorised activities; varies by change type	€600–€1,000

 VVKT state fees

The VVKT charges state application fees for pharmaceutical authorisations. Current fees are published on the VVKT website and are subject to change. For wholesale distribution authorisations, the fee is typically in the range of €300–€500. For pharmacy licences, fees vary. We confirm the current state fee at the time of each engagement and include it in the total cost estimate. State fees are payable to the VVKT directly and are separate from our service fees.

Frequently Asked Questions

Yes. A Lithuanian pharmaceutical wholesale distribution authorisation can be held by a Lithuanian company regardless of the nationality of its shareholders or directors. A Lithuanian UAB that is 100% owned by a foreign company or individual can apply for and hold a VVKT wholesale distribution authorisation on the same basis as a Lithuanian-owned company. The Qualified Person designated in the authorisation must meet the EU qualification requirements — their nationality is irrelevant. The premises must be physically located in Lithuania. We assist foreign-owned companies with the complete setup — company registration, QP identification, GDP premises assessment, and VVKT application — as a single integrated engagement.

Yes. The wholesale distribution authorisation issued by the VVKT is recognised across the EU — it is the instrument of authorisation under EU Directive 2001/83/EC, which is harmonised across all member states. A Lithuanian-licensed wholesale distributor can legally supply authorised recipients (pharmacies, hospitals, and other licensed distributors) in other EU member states without requiring a separate licence in each country. However, the products themselves must be marketing-authorised for the relevant market — supplying a product authorised only in Lithuania to a German pharmacy would require the product to have German (or EU-wide) marketing authorisation. We advise on the distinction between the wholesale distribution authorisation and the product marketing authorisation.

A VVKT GDP inspection for a wholesale distribution authorisation typically takes one full day for a single-site operation. The inspection team — usually two inspectors — will: review the quality management system documentation (quality manual, SOPs, training records, deviation logs); conduct a physical walkthrough of the warehouse premises; assess temperature monitoring systems and records; review supplier and customer verification procedures; check controlled substances storage if applicable; and interview the Qualified Person and key staff. Inspectors assess compliance against the EU GDP Guidelines. The inspection report is issued within a defined period after the inspection — typically 2–4 weeks — and identifies any deficiencies that must be remediated before the authorisation is issued.

Inspection deficiencies are classified as critical, major, or minor. Critical deficiencies — such as a non-functional temperature monitoring system or no QP in place — will prevent the authorisation from being issued until they are remediated. Major deficiencies — such as inadequate SOPs or poor documentation practices — require a corrective action plan with defined timelines. Minor deficiencies are observations that should be addressed but do not block the authorisation. Following a deficiency finding, the company must submit a CAPA (corrective and preventive action) plan to the VVKT. Depending on the severity, the VVKT may issue the authorisation conditionally on the CAPA being completed, or may require a reinspection. We prepare companies for inspections specifically to prevent first-time deficiency findings.

A pharmacist qualified in another EU member state can be the Responsible Pharmacist for a Lithuanian pharmacy, provided their qualification has been recognised by the Lithuanian Pharmacists’ Chamber (Lietuvos farmacininku rūmai). EU Directive 2005/36/EC on the recognition of professional qualifications requires Lithuania to recognise pharmacy degrees from other EU member states, subject to a recognition application to the Chamber. The recognition process typically takes 1–3 months. A pharmacist whose qualification has been recognised must register with the Chamber and obtain a Lithuanian pharmacist’s registration number before being designated as the Responsible Pharmacist.

Not necessarily — it depends on whether the product is classified as a ‘medicinal product’ under EU law. Products that make health claims but are not presented as treating or preventing disease, and that do not have a pharmacological or immunological action, are typically classified as food supplements and regulated under food law rather than pharmaceutical law. However, the classification boundary is not always clear — products at high doses, products with specific therapeutic claims, or products that are already regulated as medicines in another EU member state may be classified as medicinal products in Lithuania. A product classified as a medicinal product must be authorised through the VVKT (or EMA for centralised products), and any company distributing it must hold a wholesale distribution authorisation. We advise on product classification as part of our initial engagement for companies entering the health product market.

Whether batch testing in an EU-licensed laboratory is required for imported medicines depends on the origin country and the applicable mutual recognition agreements. For medicines manufactured in countries that have concluded a Mutual Recognition Agreement (MRA) with the EU covering batch release — including Switzerland, Australia, Japan, Canada, Israel, New Zealand, and the US — batch testing in the EU may not be required, provided the manufacturer is licensed under the MRA and the products are listed in the agreement. For medicines from all other countries — including the UK, China, and India — full batch testing in an EU GMP-licensed laboratory is required before the QP can release the batch for distribution. We advise on the applicable testing requirements for each product and country of origin at the assessment stage.

Ready to apply for your pharmaceutical licence?

Contact us to discuss your intended pharmaceutical activity, premises, and QP situation. We will confirm the correct authorisation type, assess your current readiness against GDP and VVKT requirements, and provide a scoped engagement proposal. We advise on wholesale distribution, pharmacy operation, import authorisation, and controlled substances licensing